The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•7 April 2026•

1 min read

BVF Trims MoonLake Immunotherapeutics Stake by 78% in $63 Million Sale

Fortified uniQure building, fences, caution tape, security cameras. FDA buildings, US flags, justice symbols. Charts on tablets and papers.

Key Facts

1BVF sold approximately 3.75 million shares of MoonLake Immunotherapeutics for a value of about $62.96 million.

2The sale represents a 78.30% reduction in the fund's direct holdings in the company.

Biotech Value Fund (BVF) has significantly reduced its position in MoonLake Immunotherapeutics (MLTX) through a substantial share sale. The fund offloaded approximately 3.75 million shares, valued at roughly $62.96 million. This transaction represents a massive 78.30% reduction in the fund's direct holdings in the biotechnology firm. Following the sale, BVF's direct ownership has dwindled to just over 1 million shares. While the specific motivation for the exit remains undisclosed, such large-scale liquidations by institutional investors often suggest profit-taking or portfolio rebalancing. Market analysts view this move as a potential headwind for the stock, as it may signal a shift in institutional confidence regarding near-term growth.